ArticleThe Journal of clinical investigation1990
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
Article in The Journal of clinical investigation, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 178 citations in OpenAlex.
- The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.American heart journal · 2011Trial
- High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.Journal of thrombosis and thrombolysis · 2000Trial
- Efficacy of abciximab induced platelet blockade using a rapid point of care assay.Journal of thrombosis and thrombolysis · 1999Trial
- Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function.Cardiovascular drugs and therapy · 1995Trial
- Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.International journal of cardiac imaging · 1994Trial
- Embedding a commitment to equitable global access into basic and early-phase translational research.Journal of clinical and translational science · 2025Review
- Article
- Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis.Nature communications · 2018Article
- Translational research: forging a new cultural identity.The Mount Sinai journal of medicine, New York · 2008Article
- Cell adhesion molecules: potential therapeutic & diagnostic implications.Molecular biotechnology · 2008Review
- Reduced red blood cell destruction by antibody fragments.Immunohematology · 2006Article
- Biography of Barry S. Coller.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.British journal of clinical pharmacology · 2001Article
- Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions.Journal of thrombosis and thrombolysis · 2000Review
- Applications of anti-platelet monitoring in catheterization laboratory.Journal of thrombosis and thrombolysis · 2000Review
- Antiplatelet drugs. A comparative review.Drugs · 1995Review
- Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.Journal of thrombosis and thrombolysis · 1995Article
- Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.British journal of pharmacology · 1994Article
- Thrombolytic therapy in acute myocardial infarction--selected recent developments.Annals of hematology · 1994Review
- Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa.Clinical and experimental immunology · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
The pharmacodynamics of intravenous bolus injections of 0.05, 0.10, 0.15, and 0.20 mg/kg of F(ab')2 fragments of the murine monoclonal antibody 7E3, 7E3-F(ab')2, directed against the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor of human platelets, were studied in groups of four patients with unstable angina pectoris. With 0.20 mg/kg, the template bleeding time prolonged from 6.3 +/- 1.9 (mean +/- SD) to greater than 30 min; it subsequently decreased to 13 +/- 7.8 min after 12 h and to 8.3 +/- 1.5 min after 24 h. The number of unblocked GPIIb/IIIa receptors (preinfusion value, 32,000 +/- 3,000 per platelet) decreased to 13 +/- 7% of the preinfusion value 1 h after infusion, and then increased to 33 +/- 10% at 12 h, 44 +/- 8% at 24 h and 67 +/- 7% at 72 h. The logarithm of the bleeding time was inversely proportional with the residual GPIIb/IIIa receptors (r = 0.73, P less than 0.0001). ADP-induced platelet aggregation (measured by changes in light transmittance in percent) decreased from 60 +/- 5% before infusion to 1.5 +/- 3% 1 h after infusion; it then increased to 29 +/- 3% after 24 h and 39 +/- 6% after 72 h. Platelet counts decreased by 16% at 1 h and returned to control values within 24 h. Proportionally smaller effects were seen at lower doses of 7E3-F(ab')2. Antibody injection did not induce spontaneous bleeding. Angina was not observed during the first 12 h when the bleeding time was significantly prolonged, but occurred in 6 of the 16 patients within the next 3 d. 2 of the 16 patients developed low titers of IgG antibodies specific for 7E3-F(ab')2. Thus 7E3-F(ab')2 induces dose-related inhibition of platelet function; at a dose of 0.20 mg/kg, it causes profound inhibition of platelet aggregation and prolongation of the bleeding time, but no spontaneous bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.